hat
Sou papye, gen pa parèt yo dwe anyen espesyal sou Boldenone. Men kèk reyalite de baz: Li se yon non-progestagenic, ki pa methylated 1-dehydro derive nan testostewòn, kidonk li manke efè a toksik ki asosye ak pi estewoyid nan bouch. Li posede yon A: Yon rapò 100: 50 (anabolizan / Androjenik), ki fè li apeprè mwatye kòm Androjenik kòm testostewòn ak egalman anabolizan lè yo konpare sou yon mg nan mg baz. Boldenone montre yon affinity obligatwa obligatwa pou reseptè a Androjenik pase testostewòn, men li se mwens tandans yo kole yo nan sèks Òmòn obligatwa globulin, ki gen anpil chans ede balans soti efè myotropic li yo. Dwòg la ap kenbe nivo san nan konpoze baz pou apeprè 14-16 jou pòs-piki, men de fwa chak semèn piki yo apwopriye lè eseye kenbe nivo san ki estab.
eng
On paper, there doesn’t appear to be anything special about Boldenone. Here are some basic facts: It is a non-progestagenic, non-methylated 1-dehydro derivative of testosterone, so it lacks the liver toxic effects associated with most oral steroids. It possesses an A:A ratio of 100:50 (anabolic/androgenic), making it roughly half as androgenic as testosterone and equally anabolic when compared on a mg to mg basis. Boldenone displays a weaker binding affinity for the androgen receptor than testosterone, yet it is less prone to attach to sex hormone binding globulin, which likely helps to balance out its myotropic effects. The drug will maintain blood levels of the base compound for roughly 14-16 days post-injection, yet twice weekly injections are appropriate when attempting to maintain stable blood levels.